{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:15:37Z","timestamp":1790741737824,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The DELC study enrolled 163 Japanese patients with castration-resistant prostate cancer who underwent alternative anti-androgen therapy with flutamide following failure of initial combined androgen blockade with bicalutamide in multiple institutions between January 2016 and March 2019. Primary endpoint was overall survival. Administration of enzalutamide was started at 160\u00a0mg orally once daily in all patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The rate of decline of prostate-specific antigen by 50% or more was 72.2%, and median overall survival was 42.05\u00a0months. Multivariate analysis revealed that higher pretreatment serum levels of prostate-specific antigen (\u226511.3\u00a0ng\/mL; P\u00a0=\u00a00.004), neuron-specific enolase (P\u00a0=\u00a00.014) and interleukin-6 (\u22652.15\u00a0pg\/mL; P\u00a0=\u00a00.004) were independent risk factors for overall survival. Fatigue (30.0%), constipation (19.6%) and appetite loss (17.8%) were the most common clinically relevant adverse events. The enzalutamide dose was not reduced in any patient under the age of 70, but adherence was decreased in those over 70.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the DELC study, the safety of enzalutamide was comparable to that in previous reports. Serum levels of neuron-specific enolase and interleukin-6 were suggested as prognostic factors for castration-resistant prostate cancer with potential clinical utility.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae004","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T12:28:48Z","timestamp":1706876928000},"page":"584-591","source":"Crossref","is-referenced-by-count":4,"title":["Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study"],"prefix":"10.1093","volume":"54","author":[{"given":"Akira","family":"Nagahara","sequence":"first","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"},{"name":"Department of Urology, Osaka International Cancer Institute , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-7965","authenticated-orcid":false,"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"},{"name":"Department of Urology, Fukushima Medical University , Fukushima , Japan"},{"name":"Department of Urology, Iwase General Hospital , Sukagawa, Fukushima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototaka","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Toyonaka Municipal Hospital , Toyonaka, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Rosai Hospital , Sakai, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tsujihata","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Rosai Hospital , Sakai, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Takao","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka General Medical Center , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Prefectural Nishinomiya Hospital , Nishinomiya, Hyogo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensaku","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology, National Hospital Organization Osaka National Hospital , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Police Hospital , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshichika","family":"Iwanishi","sequence":"additional","affiliation":[{"name":"Department of Urology, Sakai City Medical Center , Sakai, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kinki Central Hospital of Mutual Aid Association of Public School Teachers , Itami, Hyogo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishizuya","sequence":"additional","affiliation":[{"name":"Department of Urology, Higashiosaka City Medical Center , Higashiosaka, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Urology, Minoh City Hospital , Minoh, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Urology, Sumitomo Hospital , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Ikeda City Hospital , Ikeda, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunari","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ujike","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"},{"name":"Department of Urology, Kindai University Faculty of Medicine , Osakasayama, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka University Graduate School of Medicine , Suita, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024050715020306400_ref1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"2024050715020306400_ref2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"2024050715020306400_ref3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur Urol"},{"key":"2024050715020306400_ref4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2008.05.045","article-title":"Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade","volume":"180","author":"Suzuki","year":"2008","journal-title":"J Urol"},{"key":"2024050715020306400_ref5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/iju.13072","article-title":"Enzalutamide in Japanese patients with chemotherapy-na\u00efve, metastatic castration-resistant prostate cancer: a post-hoc analysis of the placebo-controlled PREVAIL trial","volume":"23","author":"Kimura","year":"2016","journal-title":"Int J Urol"},{"key":"2024050715020306400_ref6","first-page":"262","article-title":"Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapynaive, metastatic castration-resistant prostate cancer-updated results","volume":"47","author":"Kimura","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2024050715020306400_ref7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bco2.103","article-title":"Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study","volume":"3","author":"Uemura","year":"2022","journal-title":"BJUI Compass"},{"key":"2024050715020306400_ref8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41391-021-00318-3","article-title":"Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate","volume":"24","author":"Tagawa","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2024050715020306400_ref9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/aje\/kwaa190","article-title":"Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR Cohort)","volume":"190","author":"Scailteux","year":"2021","journal-title":"Am J Epidemiol"},{"key":"2024050715020306400_ref10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10147-019-01413-1","article-title":"Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study","volume":"24","author":"Iguchi","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2024050715020306400_ref11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bju.12452","article-title":"Inflammation and prostate cancer: the role of interleukin 6 (IL-6)","volume":"113","author":"Nguyen","year":"2014","journal-title":"BJU Int"},{"key":"2024050715020306400_ref12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-5347(01)62092-5","article-title":"Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma","volume":"161","author":"Adler","year":"1999","journal-title":"J Urol"},{"key":"2024050715020306400_ref13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"key":"2024050715020306400_ref14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H","article-title":"Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer","volume":"41","author":"Drachenberg","year":"1999","journal-title":"Prostate"},{"key":"2024050715020306400_ref15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0022-5347(05)67289-8","article-title":"Cytokine variations in patients with hormone treated prostate cancer","volume":"164","author":"Wise","year":"2000","journal-title":"J Urol"},{"key":"2024050715020306400_ref16","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1158\/1078-0432.CCR-04-1560","article-title":"The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480","volume":"11","author":"George","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2024050715020306400_ref17","first-page":"1","article-title":"Neuroendocrine and aggressive-variant prostate cancer","volume":"12","author":"Spetsieris","year":"2020","journal-title":"Cancer"},{"key":"2024050715020306400_ref18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1442-2042.2008.02015.x","article-title":"Neuroendocrine differentiation in stage D2 prostate cancers","volume":"15","author":"Kamiya","year":"2008","journal-title":"Int J Urol"},{"key":"2024050715020306400_ref19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0302-2838(03)00303-8","article-title":"Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy","volume":"44","author":"Kamiya","year":"2003","journal-title":"Eur Urol"},{"key":"2024050715020306400_ref20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1442-2042.2008.02175.x","article-title":"Neuroendocrine differentiation in the progression of prostate cancer","volume":"16","author":"Komiya","year":"2009","journal-title":"Int J Urol"},{"key":"2024050715020306400_ref21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-5347(01)69075-X","article-title":"Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer","volume":"167","author":"Isshiki","year":"2002","journal-title":"J Urol"},{"key":"2024050715020306400_ref22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.15086","article-title":"Comprehensive analysis of serum chromogranin a and neuron-specific enolase levels in localized and castration-resistant prostate cancer","volume":"127","author":"Szarvas","year":"2021","journal-title":"BJU Int"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/584\/57434896\/hyae004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/584\/57434896\/hyae004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:15:53Z","timestamp":1715094953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/5\/584\/7595935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae004","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,1]]}}}